Boston Partners’s Theravance Biopharma TBPH Stock Holding History

Boston Partners’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-53,533	Closed	-$1.94M	–	767
2016 Q3	$1.94M	Sell	53,533 -42,046	-44%	-$1.17M	﹤0.01%	661
2016 Q2	$2.17M	Buy	95,579 +3,269	+4%	+$70.6K	﹤0.01%	636
2016 Q1	$1.74M	Buy	+92,310	New	+$1.51M	﹤0.01%	638

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners's TBPH Position: Q4 2016 in Review

Boston Partners sold out of Theravance Biopharma (TBPH) in Q4 2016, closing a stake of 53,533 shares — an estimated $1.94M sold.

Boston Partners first reported a position in TBPH in Q1 2016 and held it in 3 quarters. The position peaked at $2.17M in Q2 2016. 98 funds tracked by Wall St. Rank hold TBPH as of Q4 2016.

Boston Partners reported no remaining Theravance Biopharma position as of Q4 2016 after selling out during the quarter.
Boston Partners sold 53,533 Theravance Biopharma shares in Q4 2016, an estimated $1.94M.
Boston Partners first reported a position in Theravance Biopharma in Q1 2016 and held it in 3 quarters.
Boston Partners's Theravance Biopharma position peaked at $2.17M in Q2 2016.
98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2016.

Based on Boston Partners's 13F filing for Q4 2016, filed 6 Feb 2017.